Stent formed from crosslinked bioabsorbable polymer

• US 8,846,071 B2
• Filed: 02/17/2012
• Issued: 09/30/2014
• Est. Priority Date: 04/10/2009
• Status: Active Grant

• Current Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Inventors: Kleiner, Lothar W.
• Primary Examiner(s): JONES JR., ROBERT STOCKTON
• Application Number:
  US13/399,143
• Publication Number:
  US 20120149850A1
• Time in Patent Office: 956 Days
• Field of Search: 424/426, 525/403, 525/408, 525/415, 525/450
• US Class Current: 424/426
• CPC Class Codes: A61L 31/06 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61L31/041 takes precedence
• CPC Class Codes: A61L 31/14 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 31/148 Materials at least partially resorbable by the body
• CPC Class Codes: C08G 63/46 Polyesters chemically modified by esterification C08G63/20 takes precedence; by after-treatment C08G63/91

Abstract

A stent having a stent body made from a crosslinked bioabsorbable polymer is disclosed. A method of making the stent including exposing a tube formed from a bioabsorbable polymer to radiation to crosslink the bioabsorbable polymer and forming a stent body from the exposed tube is disclosed. The tube can include a crosslinking agent which induces crosslinking upon radiation exposure. Additionally or alternatively, the bioabsorbable polymer can be a copolymer that crosslinks upon exposure to radiation in the absence of a crosslinking agent.

Claims

1. A stent comprising a stent body for supporting a vascular lumen, wherein the stent body comprises a crosslinked bioabsorbable polymer formed from crosslinking a bioabsorbable polymer, wherein the bioabsorbable polymer is a polymer formed through a transesterification reaction between a degradable polyester and a diol or a triol followed by a chain extension conducted with the degradable polyester and alkyne valerolactone.

2. The stent of claim 1, wherein the degradable polyester is PLLA and the diol is PEG or the triol is 1,1,1-tris(hydroxymethyl)ethane.

3. The stent of claim 1, wherein the degradable polyester is PLLA.

4. The stent of claim 1, wherein the diol is PEG.

5. The stent of claim 1, wherein the triol is 1,1,1-tris(hydroxymethyl)ethane.